MoonLake Immunotherapeutics (MEX:MLTXN) EBIT: MXN-4,550.49 Mil (TTM As of Mar. 2026)


MEX:MLTXN MoonLake Immunotherapeutics MEX:MLTXN
30 GF Score
Price MXN305.30
! 3 Warning Signs
View Full Analysis

What is MoonLake Immunotherapeutics EBIT?

MoonLake Immunotherapeutics MEX:MLTXN 30 EBIT is MXN-4,550.49 Mil as of Mar. 2026. GuruFocus rates MEX:MLTXN with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.

MoonLake Immunotherapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was MXN-1,204.87 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-4,550.49 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. MoonLake Immunotherapeutics's annualized ROC % for the quarter that ended in Mar. 2026 was -4,264.71%. MoonLake Immunotherapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -11,802.93%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. MoonLake Immunotherapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -18.24%.

MoonLake Immunotherapeutics  (MEX:MLTXN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

MoonLake Immunotherapeutics's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-5050.888 * ( 1 - 0% )/( (113.381 + 123.488)/ 2 )
=-5050.888/118.4345
=-4,264.71 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7642.213 - 754.799 - ( 7093.67 - max(0, 818.863 - 7592.896+7093.67))
=113.381

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7219.824 - 775.388 - ( 6454.282 - max(0, 831.56 - 7152.508+6454.282))
=123.488

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

MoonLake Immunotherapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-4819.492/( ( (38.586 + max(-385.088, 0)) + (43.08 + max(-220.666, 0)) )/ 2 )
=-4819.492/( ( 38.586 + 43.08 )/ 2 )
=-4819.492/40.833
=-11,802.93 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 411.556) - (754.799 + 0 + 41.845)
=-385.088

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 594.304) - (775.388 + 0 + 39.582)
=-220.666

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

MoonLake Immunotherapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-4550.49/24944.601
=-18.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MoonLake Immunotherapeutics EBIT Related Terms

MoonLake Immunotherapeutics EBIT Historical Data

* Premium members only.

The historical data trend for MoonLake Immunotherapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MoonLake Immunotherapeutics EBIT Chart

MoonLake Immunotherapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
0.00 -1,268.43 -746.61 -2,522.75 -4,005.58

MoonLake Immunotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -826.27 -1,015.25 -1,236.05 -1,094.31 -1,204.87

MEX:MLTXN vs AVBP, BCAX, KALV: EBIT Comparison

For the Biotechnology subindustry, MoonLake Immunotherapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MoonLake Immunotherapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MoonLake Immunotherapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MoonLake Immunotherapeutics's EV-to-EBIT falls into.


MEX:MLTXN
30GF Score
MoonLake Immunotherapeutics MEX:MLTXN
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MoonLake Immunotherapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-4,550.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of MXN-4,550.49 Mil mean?
MoonLake Immunotherapeutics (MEX:MLTXN) has a EBIT of MXN-4,550.49 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on MoonLake Immunotherapeutics.
Is MoonLake Immunotherapeutics' EBIT too high?
MoonLake Immunotherapeutics' current EBIT is MXN-4,550.49 Mil. Overall, MoonLake Immunotherapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does MoonLake Immunotherapeutics' EBIT compare to AVBP and BCAX?
MoonLake Immunotherapeutics' EBIT of MXN-4,550.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on MoonLake Immunotherapeutics. MoonLake Immunotherapeutics's current EBIT is MXN-4,550.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MoonLake Immunotherapeutics stock overvalued right now?
MoonLake Immunotherapeutics (MEX:MLTXN) has a current EBIT of MXN-4,550.49 Mil. The current EBIT is MXN-4,550.49 Mil. MoonLake Immunotherapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For MoonLake Immunotherapeutics (MEX:MLTXN), the current EBIT is MXN-4,550.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MoonLake Immunotherapeutics Business Description

Other Exchanges MLTX:USA
Address Dorfstrasse 29, Zug, CHE, 6300
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
30GF Score

Get the complete analysis for MEX:MLTXN

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN305.30
Price